AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Ultragenyx Pharmaceutical Inc.
Video analysis: RARE
All videosNo video analysis for this stock yet. Request one from our team.
News: RARE
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE
NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Ultragenyx Pharmaceutical Inc. (“Ultragenyx” or the “Company”) (NASDAQ: RARE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Why Is Ultragenyx (RARE) Up 6.4% Since Last Earnings Report?
Ultragenyx (RARE) reported earnings 30 days ago. What's next for the stock?
RARE Stock Down 46% as Phase III Angelman Syndrome Study Misses Goals
Ultragenyx plunges 46% after its phase III Angelman syndrome study fails to achieve key efficacy goals, putting apazunersen's future in question.
QUICK SPARK: Pharma Bro Martin Shkreli Says Ultragenyx Should Be M&A Target
Martin Shkreli, known as Pharma Bro, said Ultragenyx Pharmaceutical (NASDAQ:RARE) is undervalued and a potential takeover target for rare-disease peers like BioMarin Pharmaceuticals (NASDAQ:BMRN) after a trial setback.
Ultragenyx Forced To Cut Costs After Disappointing Phase 3 Results
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) stock is tumbling on Thursday after reporting late-stage clinical trial failures for its Angelman syndrome therapy, apazunersen, prompting the biopharmaceutical firm to review the program's future and plan significant corporate expense reductions.
Here Are Thursday’s Top Wall Street Analyst Research Calls: Broadcom, Deere & Company, Dell Technologies, Devon Energy, Moderna, Permian Resources, PG&E, Thermo Fisher, Viper Energy, and More
Markets wobble heading into the Labor Day weekend as bond vigilantes push back against Washington, oil stays tense with Middle East strikes escalating, and Wall Street analysts make bold calls on names ranging from Broadcom to Moderna that could reshape your portfolio positioning.
Ultragenyx Stock Sinks 47% on Drug Trial Failure. Why Wall Street Isn't Giving Up Yet.
Ultragenyx Pharmaceuticals looks to cut costs following the trial failure, while attention remains squared on its burgeoning commercial business.
Ultragenyx shares crater after Angelman syndrome drug fails late-stage trial
Shares of Ultragenyx Pharmaceutical plunged more than 40% in premarket on Thursday after its neurodevelopmental disorder treatment failed a closely watched late-stage trial, dealing a major blow to one of its biggest growth bets.
